(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 9896.139.3

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application

0					Washington, D.0	C. 20231					
			filing under 35	U.S.C.	111(a) and 37 C	.F.R. 1.53((b) is a new utility patent app	olication for an			
invention e	MEDICAMENT INCORPORATION MATRIX										
and invent	and invented by:										
Stephen D D	J. Ch	udzik, Ter	rrence P. Ever	son, and	Richard A. Amo	os.		31036			
f a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:											
_ E⊠ Conf	inuat	ion 🗆	Divisional	☐ Co	ontinuation-in-p	art (CIP)	of prior application No.:	60/225,465			
Which is a	a:										
Cont		ion 🗆	Divisional	☐ Co	ontinuation-in-p	oart (CIP)	of prior application No.:				
Which is a	inuat	ion 🗆	Divisional	□ Co	ontinuation-in-p	part (CIP)	of prior application No.: _				
Enclosed	Enclosed are: Application Elements										
1. 🛚	Filin	ın fee as d	calculated and	transm	itted as describe	ed helow					
٠. ي	1 1111	ig icc as t	carcalated and	a transm	nica as acsorbe	od BOIOW					
2. 🗵	2. Specification having pages and including the following:										
a	\times	Descript	ive Title of the	e Inventio	on						
b.	b. 🗵 Cross References to Related Applications (if applicable)										
C.	c. 🗵 Statement Regarding Federally-sponsored Research/Development (if applicable)										
d.	d. Reference to Microfiche Appendix (if applicable)										
e.	e. ⊠ Background of the Invention										
	f. 🗵 Brief Summary of the Invention										
	g. Brief Description of the Drawings (if drawings filed)										
	_ . 🗵		Description		J (,					
	_ . 🗵		as Classified	Below							
	_ . 🛛		of the Disclo								

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 9896.139.3

Total Pages in this Submission 69

3.		Drawing(s) (when necessary as prescribed by 35 USC 113)								
	a.	☐ Formal Number of Sheets								
	b.	☐ Informal Number of Sheets								
4.	\boxtimes	Oath or Declaration								
	a.	☑ Newly executed (original or copy) ☐ Unexecuted								
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)								
	C.	With Power of Attorney □ Without Power of Attorney								
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.								
6.		Computer Program in Microfiche (Appendix)								
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)								
	a.	☐ Paper Copy								
	b.	☐ Computer Readable Copy (identical to computer copy)								
,	C.	Statement Verifying Identical Paper and Computer Readable Copy								
	Accompanying Application Parts									
8.	A	Assignment Papers (cover sheet & document(s))								
9.		37 CFR 3.73(B) Statement (when there is an assignee)								
10.		English Translation Document (if applicable)								
11.		Information Disclosure Statement/PTO-1449								
12.		Preliminary Amendment								
13.	\boxtimes	Acknowledgment postcard								
14.	(2)	Certificate of Mailing								
	\boxtimes	Continuate of Manifest								

Application Elements (Continued)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

was unintentional.

Docket No. 9896.139.3

Total Pages in this Submission 69

Accompanying Application Parts (Continued) ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Additional Enclosures (please identify below): Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2) Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application. Warning An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 9896.139.3

Total Pages in this Submission 69

For								
		Fee Calcula 		ansmitta 		<u> </u>		
For	#Filed		#Extra		Rate		Fee	
Total Claims	78	- 20 =	58	x	\$18.00		\$1,044.00	
च I ndep. Claims	3	- 3 =	0	x	\$80.00		\$0.00	
্র Multiple Dependent C	laims (check i	f applicable)					\$0.00	
		·				BASIC FEE	\$710.00	
OTHER FEE (specify	OTHER FEE (specify purpose)							
					TOTAL	FILING FEE	\$1,754.00	
 A check in the amount of \$1,754.00 to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 061910 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R . 16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Dated: Of TULY 2021 Philip M. Goldman FREDRIKSON & BYRON, P.A. 1100 International Centre 900 Second Avenue South 								
cc:			M (6	linneapol 12) 347-7	is, MN 55402			